Valneva’s COVID-19 vaccine is a whole virus, inactivated, adjuvanted vaccine against COVID-19 developed and approved in Europe (conditional approval in the UK; standard approval in the European Union). Valneva initiated additional clinical trials to potentially support future approval in further age groups and as a booster.
Clinical development of Valneva’s COVID-19 vaccine candidate is ongoing
Valneva reported initial results confirming that VLA2001 boosted immunity in participants who received VLA2001 as a primary vaccination 7-8 months before (Press release). Valneva reported further homologous booster data and first heterologous booster data from its Phase 3 Cov-Compare study in August 2022 (Press release). In parallel, Valneva initiated a heterologous booster trial of VLA2001 to provide booster data following primary vaccination with an mRNA vaccine or natural COVID-19 infection. VLA2001 is not yet approved for use as a booster.
Trials with adolescents and elderly
Valneva announced the recruitment of adolescents as an expansion of the Cov-Compare trial (Press release). Valneva has also completed recruitment of 306 volunteers aged 56 years and older in New Zealand (Press release) into its VLA2001-304 trial.